Lymphangioleiomyomatosis (LAM) is a rare condition that causes cysts and other growths to form in your lungs, kidneys and lymphatic system. Symptoms include shortness of breath, chest pain and cough. It’s caused by genetic changes that allow certain cells to grow unchecked. It almost exclusively affects people assigned female at birth (AFAB).
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Lymphangioleiomyomatosis (LAM) is a rare lung disease that causes damaging cysts in your lungs. It can also cause growths in your kidneys and lymphatic system. It’s caused by genetic mutations that allow smooth muscle cells to grow uncontrollably.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Lymphangioleiomyomatosis (pronounced “limf-AN-gee-oh-ly-oh-my-oh-muh-TOH-sis”) mostly affects people assigned female at birth (AFAB). Most people are diagnosed between the ages of 20 and 40, or between puberty and menopause. Because of this, experts believe the hormone estrogen or having a uterus may play a role in cyst development.
There are two types of LAM:
LAM is rare. Fewer than 1 in 140,00 people AFAB has sporadic LAM. Anywhere between 30% to 80% of people AFAB with tuberous sclerosis also have LAM.
Symptoms of LAM include:
Mutations (changes) in two genes (TSC1 and TSC2) can cause LAM. TSC1 and TSC2 are tumor suppressor genes. They keep certain cells from multiplying out of control. When one of them has a mutation, smooth muscle cells multiply when they shouldn’t. This causes:
Advertisement
You can either inherit an abnormal copy of TSC1 or TSC2 from a biological parent who has one, or changes to the gene can be spontaneous (we don’t know why it happens). Inherited changes in TSC1 or TSC2 cause tuberous sclerosis. More than 30% of people AFAB with tuberous sclerosis have LAM. Changes to TSC2 that you didn’t inherit cause sporadic LAM, without additional symptoms of tuberous sclerosis.
LAM almost exclusively affects people AFAB. Only a few people assigned male at birth (AMAB) have ever received a LAM diagnosis. There’s only one known case of someone AMAB with sporadic LAM. LAM often gets worse during pregnancy and while using medications that contain estrogen.
A collapsed lung (pneumothorax) is the most common complication of LAM. Over half of all people with LAM will have a collapsed lung at least once, and they often recur. Many people with LAM are diagnosed after experiencing lung collapse.
Other complications include:
To diagnose LAM, a healthcare provider will examine you and ask about your symptoms. They’ll order or perform tests and imaging to better understand:
Symptoms of lymphangioleiomyomatosis are similar to those of other, more common lung conditions, so it can be hard for healthcare providers to diagnose.
You may need the following tests and procedures:
There’s no cure for LAM. But the medication sirolimus (also known as rapamycin, or by the brand name Rapamune®) can stabilize it and keep it from getting worse. Sirolimus can also shrink kidney growths (angiomyolipomas), shrink lymphatic masses and fluid collection, and reduce your symptoms.
Advertisement
Other treatments might include:
Sirolimus can cause severe kidney damage and make you more likely to get serious infections. Talk to your provider about the risks and benefits of taking it.
LAM can get worse over time, and your treatments may change depending on what’s working for you. You’ll work with a pulmonologist (a healthcare provider who specializes in the lungs) to determine the best way to monitor your condition. They’ll test your lung function periodically. Your provider will individualize your treatment based on your:
How fast LAM progresses can vary from person to person and can depend on many factors, including:
Advertisement
Many people with LAM (64%) can live 20 years or more after their diagnosis before needing a lung transplant. But because LAM cells don’t start in your lungs, cysts can come back, even after a transplant.
Your life expectancy with LAM depends on the severity and how fast it’s progressing. But overall, the outlook is more positive than it was in the past. More than 90% of people with LAM are alive 10 years after their diagnosis.
Talk to your pulmonologist about what to expect and how to make a plan to manage LAM. Keep all of your follow-up appointments and take your medications as directed. Let your provider know about any new or worsening symptoms or if you have concerning side effects from your treatment.
If you have shortness of breath, a cough or other concerning symptoms that don’t go away or get worse over time, talk to a healthcare provider.
Go to the emergency room or seek immediate medical attention if you have signs of a collapsed lung or other serious symptoms, such as:
It might be helpful to ask your healthcare provider:
Advertisement
LAM isn’t usually considered cancer. In some ways it acts like metastatic cancer — the cells seem to start somewhere else and move through your blood vessels and lymph system to your lungs and kidneys. The way it grows is sometimes called benign cell metastasis.
But scientists aren’t exactly sure where the cells start. And the growths don’t seem to spread widely to organs like your liver and brain like cancer does. Under a microscope, the cells look more like normal cells rather than cancer cells.
A note from Cleveland Clinic
Thanks to new treatments and a better understanding of LAM, people are living longer without a lung transplant. Still, the adjustment to a new way of life will take time. Finding out you have a lifelong condition can be like getting the rug pulled out from under you. But your healthcare team — and your personal support team — can help you find your footing again.
Last reviewed on 11/14/2023.
Learn more about the Health Library and our editorial process.